ACS Dobfar S.p.A. is a privately owned, fully integrated global pharmaceutical company headquartered in Italy. Founded in 1973, it specializes in the research, development, manufacturing, and commercialization of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company is a key player in the antibiotics market, particularly known for its expertise in cephalosporins and carbapenems. ACS Dobfar operates multiple cGMP-approved manufacturing facilities and R&D centers, serving pharmaceutical companies worldwide with high-quality products and a commitment to innovation and sustainability.
Serves as the central hub for strategic decision-making, global operations management, research and development leadership, and corporate functions including finance, HR, and global sales.
The headquarters likely houses advanced administrative offices and may be co-located with or near key R&D facilities, reflecting its core business in pharmaceutical innovation.
The work culture at ACS Dobfar HQ is expected to be scientifically driven, quality-focused, and collaborative, with an emphasis on innovation, precision in manufacturing, and adherence to strict regulatory standards typical of the pharmaceutical industry.
Its location in the Lombardy region, a significant industrial and pharmaceutical hub in Italy and Europe, provides access to skilled talent, research institutions, and logistical networks, crucial for its global operations.
ACS Dobfar has a significant global presence, exporting its Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) to over 100 countries worldwide. While its manufacturing and R&D operations are primarily concentrated in Italy, its commercial reach is extensive, supported by a global sales and distribution network. Key functions supported globally include product registration, quality assurance, customer support, and market access for its specialized antibiotic portfolio.
Viale Addetta, 4/12
Tribiano
MI (Metropolitan City of Milan)
Italy
Address: Via Provinciale Novedratese, 115, 22040 Anzano del Parco CO, Italy
Serves as a major production facility for European and global markets, leveraging regional expertise in pharmaceutical manufacturing and strict quality control.
Address: S.S. 87 Z.I., 86039 Termoli CB, Italy
Supports the company's production capacity and supply chain resilience, catering to global demand for its pharmaceutical products.
Address: S.S. 7 Z.I. BR/3, 72100 Brindisi BR, Italy
Enhances ACS Dobfar's manufacturing footprint in Southern Italy, supporting its integrated supply chain for global distribution.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, ACS DOBFAR' leadership includes:
ACS DOBFAR has been backed by several prominent investors over the years, including:
As a privately held company, detailed executive movements are not always broadly publicized. No major high-profile executive hires or exits have been widely reported for ACS Dobfar in the immediate last 12 months through standard news channels. Leadership appears relatively stable following its acquisition by CVC Capital Partners.
Discover the tools ACS DOBFAR uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
ACS Dobfar likely utilizes a standard corporate email format. Based on common practices in Italian and international companies, the most probable format is [first_initial].[last_name]@acsdobfar.com or [first_name].[last_name]@acsdobfar.com.
f.lastname@acsdobfar.com or firstname.lastname@acsdobfar.com
Format
m.falciani@acsdobfar.com
Example
80%
Success rate
European Pharmaceutical Review • January 24, 2024
ACS Dobfar and Olon S.p.A. have partnered to enhance the sustainability of Active Pharmaceutical Ingredient (API) production through innovative processes. The collaboration aims to reduce the environmental impact and improve the efficiency of API manufacturing, focusing on green chemistry and sustainable sourcing for critical antibiotic components....more
ACS Dobfar Website (Press Release section or equivalent) • October 19, 2023
ACS Dobfar announced new sustainability targets aimed at significantly reducing its carbon footprint across its manufacturing operations by 2030. This initiative includes investments in renewable energy sources and process optimization to enhance energy efficiency, underscoring its commitment to environmental stewardship....more
CVC Capital Partners • July 5, 2019
CVC Capital Partners Fund VII announced its agreement to acquire ACS Dobfar, a leading international generic pharmaceuticals company. The investment aims to support ACS Dobfar's continued growth, innovation in API and FDF development, and expansion of its global market reach....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including ACS DOBFAR, are just a search away.